Stable angina

Current state of disease management

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

OBJECTIVE: To describe the epidemiology, impact, pathogenesis, patient presentation, and treatment of stable angina, including the use of vasculoprotective and antianginal drug therapies and coronary revascularization procedures. SUMMARY: Stable angina is an age-related condition that typically affects men at an earlier age than women, adversely affects quality of life, and increases mortality. Stable angina is the result of an increase in myocardial oxygen demand in the setting of coronary arteries chronically narrowed by large, stable atherosclerotic plaques and a diminished myocardial oxygen supply. The characteristics of the chest pain or discomfort contribute to the clinical presentation. Treatment guidelines call for efforts to modify CHD risk, antianginal drug therapy, and patient education. Angiotensin-converting enzyme inhibitors and low-dose aspirin or clopidogrel may be used to reduce the risk of myocardial infarction and death. A beta-blocker or a nondihydropyridine calcium channel blocker may be used as initial antianginal drug therapy, and a long-acting nitrate or dihydropyridine calcium channel blocker may be added. The choice among antianginal drug therapies often hinges on patient characteristics, contraindications, and adverse effects. Revascularization with percutaneous coronary intervention or coronary artery bypass graft surgery is an option for ischemia refractory to maximum tolerated dosages of antianginal therapy. CONCLUSION: Various drug therapies may be used to manage stable angina, with coronary revascularization as an option in patients who are refractory to drug therapy. However, antianginal drug therapies may prove inadequate for managing anginal episodes for a variety of reasons, and revascularization is not always effective. Copyright

Original languageEnglish (US)
JournalJournal of Managed Care Pharmacy
Volume12
Issue number8 SUPPL.
StatePublished - Oct 1 2006

Fingerprint

Drug therapy
Stable Angina
Disease Management
Drug Therapy
clopidogrel
Calcium Channel Blockers
Refractory materials
Oxygen
Oxygen supply
Epidemiology
Atherosclerotic Plaques
Patient Education
Percutaneous Coronary Intervention
Hinges
Chest Pain
Angiotensin-Converting Enzyme Inhibitors
Grafts
Coronary Artery Bypass
Nitrates
Surgery

Keywords

  • Burden of disease
  • Pharmacotherapy
  • Revascularization
  • Stable angina
  • Treatment guidelines

ASJC Scopus subject areas

  • Pharmaceutical Science
  • Health Policy
  • Pharmacy

Cite this

Stable angina : Current state of disease management. / Dobesh, Paul P.

In: Journal of Managed Care Pharmacy, Vol. 12, No. 8 SUPPL., 01.10.2006.

Research output: Contribution to journalArticle

@article{6f83c37a384b45e89f9ed158f7757896,
title = "Stable angina: Current state of disease management",
abstract = "OBJECTIVE: To describe the epidemiology, impact, pathogenesis, patient presentation, and treatment of stable angina, including the use of vasculoprotective and antianginal drug therapies and coronary revascularization procedures. SUMMARY: Stable angina is an age-related condition that typically affects men at an earlier age than women, adversely affects quality of life, and increases mortality. Stable angina is the result of an increase in myocardial oxygen demand in the setting of coronary arteries chronically narrowed by large, stable atherosclerotic plaques and a diminished myocardial oxygen supply. The characteristics of the chest pain or discomfort contribute to the clinical presentation. Treatment guidelines call for efforts to modify CHD risk, antianginal drug therapy, and patient education. Angiotensin-converting enzyme inhibitors and low-dose aspirin or clopidogrel may be used to reduce the risk of myocardial infarction and death. A beta-blocker or a nondihydropyridine calcium channel blocker may be used as initial antianginal drug therapy, and a long-acting nitrate or dihydropyridine calcium channel blocker may be added. The choice among antianginal drug therapies often hinges on patient characteristics, contraindications, and adverse effects. Revascularization with percutaneous coronary intervention or coronary artery bypass graft surgery is an option for ischemia refractory to maximum tolerated dosages of antianginal therapy. CONCLUSION: Various drug therapies may be used to manage stable angina, with coronary revascularization as an option in patients who are refractory to drug therapy. However, antianginal drug therapies may prove inadequate for managing anginal episodes for a variety of reasons, and revascularization is not always effective. Copyright",
keywords = "Burden of disease, Pharmacotherapy, Revascularization, Stable angina, Treatment guidelines",
author = "Dobesh, {Paul P}",
year = "2006",
month = "10",
day = "1",
language = "English (US)",
volume = "12",
journal = "Journal of managed care & specialty pharmacy",
issn = "2376-0540",
publisher = "Academy of Managed Care Pharmacy (AMCP)",
number = "8 SUPPL.",

}

TY - JOUR

T1 - Stable angina

T2 - Current state of disease management

AU - Dobesh, Paul P

PY - 2006/10/1

Y1 - 2006/10/1

N2 - OBJECTIVE: To describe the epidemiology, impact, pathogenesis, patient presentation, and treatment of stable angina, including the use of vasculoprotective and antianginal drug therapies and coronary revascularization procedures. SUMMARY: Stable angina is an age-related condition that typically affects men at an earlier age than women, adversely affects quality of life, and increases mortality. Stable angina is the result of an increase in myocardial oxygen demand in the setting of coronary arteries chronically narrowed by large, stable atherosclerotic plaques and a diminished myocardial oxygen supply. The characteristics of the chest pain or discomfort contribute to the clinical presentation. Treatment guidelines call for efforts to modify CHD risk, antianginal drug therapy, and patient education. Angiotensin-converting enzyme inhibitors and low-dose aspirin or clopidogrel may be used to reduce the risk of myocardial infarction and death. A beta-blocker or a nondihydropyridine calcium channel blocker may be used as initial antianginal drug therapy, and a long-acting nitrate or dihydropyridine calcium channel blocker may be added. The choice among antianginal drug therapies often hinges on patient characteristics, contraindications, and adverse effects. Revascularization with percutaneous coronary intervention or coronary artery bypass graft surgery is an option for ischemia refractory to maximum tolerated dosages of antianginal therapy. CONCLUSION: Various drug therapies may be used to manage stable angina, with coronary revascularization as an option in patients who are refractory to drug therapy. However, antianginal drug therapies may prove inadequate for managing anginal episodes for a variety of reasons, and revascularization is not always effective. Copyright

AB - OBJECTIVE: To describe the epidemiology, impact, pathogenesis, patient presentation, and treatment of stable angina, including the use of vasculoprotective and antianginal drug therapies and coronary revascularization procedures. SUMMARY: Stable angina is an age-related condition that typically affects men at an earlier age than women, adversely affects quality of life, and increases mortality. Stable angina is the result of an increase in myocardial oxygen demand in the setting of coronary arteries chronically narrowed by large, stable atherosclerotic plaques and a diminished myocardial oxygen supply. The characteristics of the chest pain or discomfort contribute to the clinical presentation. Treatment guidelines call for efforts to modify CHD risk, antianginal drug therapy, and patient education. Angiotensin-converting enzyme inhibitors and low-dose aspirin or clopidogrel may be used to reduce the risk of myocardial infarction and death. A beta-blocker or a nondihydropyridine calcium channel blocker may be used as initial antianginal drug therapy, and a long-acting nitrate or dihydropyridine calcium channel blocker may be added. The choice among antianginal drug therapies often hinges on patient characteristics, contraindications, and adverse effects. Revascularization with percutaneous coronary intervention or coronary artery bypass graft surgery is an option for ischemia refractory to maximum tolerated dosages of antianginal therapy. CONCLUSION: Various drug therapies may be used to manage stable angina, with coronary revascularization as an option in patients who are refractory to drug therapy. However, antianginal drug therapies may prove inadequate for managing anginal episodes for a variety of reasons, and revascularization is not always effective. Copyright

KW - Burden of disease

KW - Pharmacotherapy

KW - Revascularization

KW - Stable angina

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=34548551493&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548551493&partnerID=8YFLogxK

M3 - Article

VL - 12

JO - Journal of managed care & specialty pharmacy

JF - Journal of managed care & specialty pharmacy

SN - 2376-0540

IS - 8 SUPPL.

ER -